Uptime’s 13th Annual Global Data Center Survey Shows Widening Range of Challenges
18.7.2023 13:03:00 EEST | Business Wire | Press release
Uptime Institute today announced the release of its 13th Annual Global Data Center survey. The findings show data center operators facing stricter regulations and more pressure to reduce energy, along with persistent staffing and supply chain issues. The Report shows new technologies potentially presenting a promising way forward, but these often are found lacking in standardization and scalability. While for many organizations, investments in efficiency and resiliency are beginning to pay off, progress has been gradual.
“Our data shows operators grappling with several issues,” said Andy Lawrence, executive director, Uptime Intelligence. “In 2023, the lingering effects of the COVID-19 pandemic have receded, but other challenges have emerged. Digital infrastructure managers are now most concerned with improving energy performance and dealing with staffing shortfalls, while Government regulations aimed at improving data center sustainability and visibility are beginning to require attention, investment, and action.”
Uptime’s Annual Global Data Center survey is the largest, most comprehensive, and longest-running study in the digital infrastructure sector. It provides detailed insights into the digital infrastructure landscape and a view into its future trajectory. Key findings from the 2023 report include:
- Average global power usage effectiveness (PUE) levels have remained flat for four years. Additional improvements in PUE levels will require significant investment.
- As more organizations opt for a hybrid approach to IT, the share of enterprise workloads that are run in corporate, on-premises facilities has fallen to below half for the first time and is expected to shrink further.
- Enterprise operators say data security is the biggest impediment to moving mission-critical workloads to the public cloud. Resiliency and transparency are lesser concerns.
- Server rack densities are climbing steadily, but slowly. Average rack densities are below 6 kilowatt (kW) per rack; most operators do not have any racks beyond 20 kW. This suggests the widespread use of direct liquid cooling is not imminent.
- Many operators only collect a limited amount of sustainability related data and will struggle to meet emerging sustainability reporting requirements, or in turn, the requirements of some customers and the public.
- Most operators believe acceptance of the use of artificial intelligence will grow in data centers, but operators are distrustful of its ability to make reliable operational decisions.
Outages:
- More than half (55%) of operators reported they have had an outage at their site in the past three years, the lowest number yet recorded. This continues a trend of steady improvement.
- Power outages continue to be cited as the single biggest cause of outages.
Staffing:
- Uptime Intelligence data shows that approximately 8% of the data center workforce are women. In the US (if not all countries), this rate is below that of other male-dominated industries, such as mining and construction.
- Nearly two-thirds of operators have problems recruiting or retaining staff – however, this figure is not currently growing. The largest skill gaps are in operations, mechanical and electrical roles.
About the Survey:
Uptime conducted this year’s annual Global Data Center Survey online from February – April 2023 and collected responses from more than 850 data center owners and operators and nearly 700 vendors and consultants.
Learn More:
Uptime’s 2023 Global Data Center Survey also includes findings on regulatory support, sustainability, and metrics, staffing shortfalls, skills gaps, diversity, innovation and impact, and more. Download the executive summary report here and register for the webinar covering its key trends and takeaways on July 18th at 12:00 PM EDT, 5:00 PM BST.
About Uptime:
Uptime Institute is the Global Digital Infrastructure Authority. For over 25 years, the company has established industry-leading benchmarks for data center performance, resilience, sustainability, and efficiency, which provide customers assurance that their digital infrastructure can perform across a wide array of operating conditions at a level consistent with their business needs. Uptime’s Tier Standard is the IT industry’s most trusted and adopted global standard for the design, construction, and operation of data centers. With its Tier Standard and Certifications, Management & Operations reviews, SCIRA-FSI financial sector risk assessment, broad range of additional risk and performance assessments, intelligence research service, and training courses completed by over 10,000 data center professionals, Uptime has helped thousands of companies in over 114 countries to optimize critical IT assets while managing costs, resources, and efficiency.
Uptime Institute is headquartered in New York, NY, with offices in London, Sao Paulo, Dubai, Riyadh, Singapore, and Taipei. For more information, please visit www.uptimeinstitute.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230718020841/en/
Contact information
Brenda South
206/706-4647
bsouth@uptimeinstitute.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
